New results from VOICE associates tenofovir gel use with lower HSV-2 risk in women

Analysis found risk reduced by 46 percent in women who used gel regularly; Affirms results of CAPRISA 004 trial

2014-10-28

(Press-News.org) CAPE TOWN, October 28, 2014 – The risk of acquiring herpes simplex virus type 2 (HSV-2) was reduced by half among women in the VOICE trial who used a vaginal gel containing the antiretroviral (ARV) drug tenofovir regularly, according to researchers from the U.S. National Institutes of Health-funded Microbicide Trials Network (MTN) who conducted the study. The findings provide additional evidence that tenofovir gel, a product developed to protect against HIV, could potentially help in preventing one of the most prevalent sexually transmitted infections affecting sexually active women in sub-Saharan Africa.

No biomedical prevention method currently exists for HSV-2, the most common cause of genital herpes. Women are especially susceptible to infection because it is more easily transmitted from an infected man to his female sex partner than from a woman to a man. Because HSV-2 infection also greatly enhances the risk of acquiring and transmitting HIV, a product that protects against HSV-2 could have an important public health impact.

The results, which were based on an analysis of data involving more than 500 women in VOICE, were reported at the HIV Research for Prevention (HIV R4P) meeting in Cape Town today. Jeanne Marrazzo, M.D., M.P.H., from the University of Washington, presented the results on behalf of the VOICE study team.

VOICE – Vaginal and Oral Interventions to Control the Epidemic – was designed to test the safety and effectiveness of different ARV approaches used daily for preventing HIV among 5,029 women from 15 sites in South Africa, Uganda and Zimbabwe. The study's primary results, which were reported in March 2013, found none of the products tested (tenofovir tablets, tenofovir/emtricitabine tablets – also known as Truvada®, and tenofovir gel) was effective in preventing HIV and that most participants had not used their assigned product daily as recommended. Drug was detected in less than a third of blood samples from women who were assigned to use either of the ARV tablets and in less than a quarter of samples from women asked to use tenofovir gel.

While the main questions VOICE was designed to ask concerned prevention of HIV, the team amended the protocol to explore whether any of these products also helped to protect women from acquiring HSV in response to results from another study called CAPRISA 004. CAPRISA 004 found tenofovir gel used before and after sex reduced the risk of HIV by 39 percent, a finding that was considered a major milestone for the field. But the study of 889 women in South Africa unexpectedly found that tenofovir gel also reduced the risk of HSV-2 by 51 percent compared to placebo, the first time that any kind of biomedical prevention method was shown to be effective against HSV-2.

There was very little difference in rates of HSV-2 acquisition between the tenofovir gel and placebo gel groups in VOICE, most likely because adherence to product use in the trial was low overall, Dr. Marrazzo believes. So, she and colleagues decided to focus their investigation on the women who they knew had used their product according to tests that detect the presence of drug in stored blood samples.

"In this closer examination, we saw tenofovir gel was associated with a significant reduction in HSV-2 risk. The difference was actually quite profound between the two groups of women – those who used the gel and those who hadn't," commented Dr. Marrazzo, who led the VOICE study with Zvavahera Mike Chirenje, University of Zimbabwe-University of San Francisco (UZ-UCSF).

Women who used the gel regularly were 46 percent less likely to acquire HSV-2 compared to women who seldom or never used the gel (who had no detectable drug in their blood samples), a finding that was statistically significant and was adjusted to account for other potential risk factors, including age, marital status and number of sex partners.

There were 1,004 women in VOICE who had been assigned to use tenofovir gel, 566 of whom were HSV-2 negative at the time they enrolled. The analysis involved 527 of these women for whom blood samples from both their first quarterly visit and when the exited the study could be compared, which on average represented about one year on product. Of this cohort, 92 women acquired HSV-2, 77 of whom had no detectable drug in their blood samples versus 15 among women whose blood levels indicated regular use of tenofovir gel. Accordingly, HSV-2 incidence was 20.2 percent in women who didn't use the gel compared to 11.6 percent in women who did.

Dr. Marrazzo cautioned that while the results are very encouraging, additional data is still needed. FACTS 001, a Phase III trial that tested tenofovir gel used before and after sex (the same regimen as in CAPRISA 004), was designed specifically to determine whether the gel was safe and effective in reducing the risk of HSV-2 as well as HIV among 2,059 women in South Africa. Those results are anticipated to be available early 2015.

INFORMATION:

This work was supported by the U.S. National Institutes of Health grants UM1AI068633, UM1AI068615, UM1AI106707.

VOICE was funded by the National Institute of Allergy and Infectious Diseases (NIAID), with co-funding from the Eunice Kennedy Shriver Institute for Child Health and Human Development and the National Institute of Mental Health, all components of the U.S. National Institutes of Health. The study products were provided by Gilead Sciences, Inc., of Foster City, Calif., and by CONRAD, of Arlington, Va. Viread (oral tenofovir) and Truvada are registered trademarks of Gilead Sciences. In 2006, Gilead assigned a royalty-free license for tenofovir gel to CONRAD and the International Partnership for Microbicides of Silver Spring, Md.

More information about VOICE can be found at http://www.mtnstopshiv.org/news/studies/mtn003

R4P HIV abstract (OA10.06 LB)

Association of Tenofovir (TFV) Detection with Reduced Risk of Herpes Simplex virus Type-2 (HSV-2) Acquisition in the VOICE (MTN 003) Study

Jeanne Marrazzo1, Lorna Rabe2, Cliff Kelly3, Edward Livant2, Z. Mike Chirenje4, Barbra Richardson3, James Dai3, Jeanna Piper5, Sharon Hillier2, the VOICE Study Team

1University of Washington, Seattle, WA, United States, 2Magee Women Research Institute, Pittsburgh, PA, United States, 3SCHARP - FHCRC, Seattle, WA, United States, 4University of California San Francisco Research Programme, Harare, Zimbabwe, 5DAIDS, NIAID, NIH, Bethesda, MD, United States

About the MTN

The Microbicide Trials Network (MTN) is an HIV/AIDS clinical trials network established in 2006 by the National Institute of Allergy and Infectious Diseases with co-funding from the Eunice Kennedy Shriver National Institute of Child Health and Human Development and the National Institute of Mental Health, all components of the U.S. National Institutes of Health. Based at Magee-Womens Research Institute and the University of Pittsburgh, the MTN brings together international investigators and community and industry partners whose work is focused on the development and rigorous evaluation of promising microbicides – products applied inside the vagina or rectum that are intended to prevent the sexual transmission of HIV – from the earliest phases of clinical study to large-scale trials that support potential licensure of these products for widespread use. More information about the MTN is available at http://www.mtnstopshiv.org.

ELSE PRESS RELEASES FROM THIS DATE:

What's in a name? Everything -- if you're a fruit fly

2014-10-28

A global research effort has finally resolved a major biosecurity issue: four of the world's most destructive agricultural pests are actually one and the same. For twenty years some of the world's most damaging pest fruit flies have been almost impossible to distinguish from each other. The ability to identify pests is central to quarantine, trade, pest management and basic research. In 2009 a coordinated research effort got underway to definitively answer this question by resolving the differences, if any, between five of the most destructive fruit flies: the Oriental ...

Variation in antibiotic bacteria in tropical forest soils may play a role in diversity

2014-10-28

Antibiotic-producing bacteria in soil are the source of many antibiotics used to combat diseases in humans and plants. But, surprisingly little is known about how these microbes impact tropical plant communities and ecosystems, where plant diversity, competition, and pathogen pressures are high. A study published October 28 in the journal Biotropica represents a step toward a better understanding of the role antibiotic-bacteria play in the ecology of tropical forests. University of Minnesota researchers, led by Kristen Becklund, found that antibiotic production by soil ...

World losing 2,000 hectares of farm soil daily to salt damage: UN University

2014-10-28

Every day for more than 20 years, an average of 2,000 hectares of irrigated land in arid and semi-arid areas across 75 countries have been degraded by salt, according to a study by UN University's Canadian-based Institute for Water, Environment and Health, published Oct. 28. Today an area the size of France is affected -- about 62 million hectares (20%) of the world's irrigated lands, up from 45 million hectares in the early 1990s. Salt-degradation occurs in arid and semi-arid regions where rainfall is too low to maintain regular percolation of rainwater through the ...

Screening with tomosynthesis and mammography is cost-effective

2014-10-28

OAK BROOK, Ill. – Adding tomosynthesis to biennial digital mammography screening for women with dense breasts is likely to improve breast cancer detection at a reasonable cost relative to biennial mammography screening alone, according to a new study published online in the journal Radiology. Mammography remains the only screening test proven to decrease mortality from breast cancer. However, mammography is less accurate in women with dense breasts for whom cancers may be masked by overlapping breast tissue. Moreover, dense breasts compared to average density ...

Social host laws tied to less underage drinking

2014-10-28

PISCATAWAY, NJ – Teenagers who live in communities with strict "social host" laws are less likely to spend their weekends drinking at parties, according to a study in the November issue of the Journal of Studies on Alcohol and Drugs. Many U.S. states and local communities have passed social host laws, which hold adults responsible when underage drinkers imbibe on their property. The details of the laws vary, however, and research has been mixed as to whether they actually keep kids from drinking. In the new study, investigators focused on 50 communities in California, ...

Robotically assisted bypass surgery reduces complications after surgery and cuts recovery

2014-10-28

VANCOUVER ─ Robotically assisted coronary artery bypass grafting (CABG) surgery is a rapidly evolving technology that shortens hospital stays and reduces the need for blood products, while decreasing recovery times, making the procedure safer and less risky, says a study presented at the Canadian Cardiovascular Congress. "Robotically assisted CABG is a safe and feasible alternative approach to standard bypass surgery in properly selected patients. It is a less traumatic and less invasive approach than regular CABG," says cardiac surgeon and researcher Dr. Richard ...

Radiation exposure linked to aggressive thyroid cancers

2014-10-28

For the first time, researchers have found that exposure to radioactive iodine is associated with more aggressive forms of thyroid cancer, according to a careful study of nearly 12,000 people in Belarus who were exposed when they were children or adolescents to fallout from the 1986 Chernobyl nuclear power plant accident. Researchers examined thyroid cancers diagnosed up to two decades after the Chernobyl accident and found that higher thyroid radiation doses estimated from measurements taken shortly after the accident were associated with more aggressive tumor features. "Our ...

Women play dangerous waiting game with heart symptoms

2014-10-28

VANCOUVER ─ When heart symptoms strike, men and women go through similar stages of pain but women are more likely to delay seeking care and can put their health at risk, according to a study presented at the Canadian Cardiovascular Congress. "The main danger is that when someone comes to the hospital with a more severe or advanced stage of heart disease, there are simply fewer treatment options available," says Dr. Catherine Kreatsoulas, lead author of the study and a Fulbright Scholar and Heart and Stroke Foundation Research Fellow at the Harvard School of Public ...

Prostate cancer risk reduced by sleeping with many women, but increased with many men

2014-10-28

This news release is available in French. Compared to men who have had only one partner during their lifetime, having sex with more than 20 women is associated with a 28% lower risk of one day being diagnosed with prostate cancer, according to researchers at the University of Montreal and INRS - Institut Armand-Frappier. However, having more than 20 male partners in one's lifetime is associated with a twofold higher risk of getting prostate cancer compared to those who have never slept with a man. Marie-Elise Parent and Marie-Claude Rousseau, professors at university's ...

Future-focused women stand up to global warming with taxes, checkbook

2014-10-27

PULLMAN, Wash. - Politicians who discredit global warming risk losing a big chunk of the female vote. A new study found women who consider the long-term consequences of their actions are more likely to adopt a liberal political orientation and take consumer and political steps to reduce global warming. Jeff Joireman, associate professor of marketing at Washington State University, demonstrated that "future-oriented" women are the voting bloc most strongly motivated to invest money, time and taxes toward reducing global warming. Previous studies have shown that women ...